

WARHOL MAO72 CHF TRACKER CERTIFICATE

Investing in Blue-Chip Art. Andy Warhol ranked as the 2nd top-selling artist at auction between 2015 and 2023 by lot sold with total sales reaching.

ADVERTISING

FACTSHEET AS OF AUGUST 2025

INVESTMENT STRATEGY

Andy Warhol's "Mao" (1972) is currently owned by a renown foundation in Spain. While Mao paintings primarily appear at auction in London and New York, prominent Asian collectors emerged as successful bidders, signaling the global appeal for these iconic works. In 2017, a Mao painting set a record as the highest price paid for any contemporary artwork sold in Asia¹.

PRODUCT

- Tracker Certificate
- 100% collateralized by the Art Share 004 S.A. Class B Shares ISIN: LU3018062649 (with a cash buffer of up to 5%)
- No leverage, no derivatives

HISTORICAL PERFORMANCE



Art Performance: Artprice100 index².
+9.5% CAGR over 2000-2024.

Market: in 2022 Warhol's Shot Sage Blue Marilyn (1964) became the 2nd most expensive artwork (195 Mio USD) ever sold at auction. Performance of +13.4% CAGR for Mao paintings (resold between 2004-2023), with +19.2% CAGR achieved by the early Maos.

¹Source: ArtExplored

²The Artprice100[®] index is designed as a portfolio of artworks representing the one hundred most important artists on the art market. It is used for illustration purposes only - Copyright© 2019 Thierry Ehrmann - www.artprice.com - www.artmarket.com

³Past performance is not indicative of future results.

ABOUT ARTEX

ARTEX Global Markets AG is the first regulated traditional trading venue dedicated to listing and the continuous trading of common shares in companies whose sole asset is one iconic, "Blue-chip" masterpiece painting. Operating under MiFID II regulations, ARTEX Global Markets AG is licensed within the European Economic Area (EEA), ensuring a transparent and secure trading environment. The platform provides a compliant, accessible and diversified investment alternative, promising long-term capital appreciation.

ARTEX

GLOBAL MARKETS

REFERENCE - DATA

Issuer:	Helveteq AG
Valor:	144275696
ISIN:	CH1442756966
Currency:	CHF
Issue price:	CHF 92 - CHF 94
Issue size securities:	up to 137'500
Revenue:	long-term growth

TRADE DATA

Issue date:	30 Sep 2025
Subscription period:	27. Apr 2025 until 26. Sep 2025
Maturity:	open end
Investor Fee:	0.25% p.a.
Subscription Fee:	up to 100%

SERVICE PROVIDER

Custodian:	Credinvest
Paying Agent:	Credinvest
Administrator:	Apex
Security Agent:	Adexas

CONTACT

Helveteq AG
Zentrum Staldenbach 3
8808 Pfäffikon SZ
Schweiz
+41 (0)41 554 50 99
info@helveteq.com
www.helveteq.com

*DISCLAIMER

Nothing in this transmission constitutes, may be used for the purpose of, or may be construed as, an invitation, an offer or a solicitation of securities for sale or for subscription in any jurisdiction where it is unlawful to do so. The information is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this transmission or its accuracy or completeness. The information in this transmission is subject to change. Past performance is not an indication or guarantee of future results. The charts and graphs may reflect hypothetical historical performance. All information presented prior to the issue date is back-tested. Back-tested performance is not actual performance but is hypothetical. The Products do not constitute collective investment schemes within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA), as amended from time to time, and are, therefore, neither governed by the CISA nor subject to authorization and supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, holders of these Products do not have the benefit of the specific investor protection provided under the CISA. The Issuer is not and will not be regulated by any regulator as a result of issuing the Products. The issuer is neither licensed nor registered with the Swiss Financial Market Supervisory Authority (FINMA).

THE PRODUCTS ARE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR ANY PERSON OR ADDRESS IN THE UNITED STATES OR IN ANY OTHER JURISDICTION TO WHICH A DISTRIBUTION WOULD BE UNLAWFUL. The Products have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act) or with any securities regulatory authority of any State or other jurisdiction of the United States and (i) may not be offered, sold or delivered within the United States to, or for the account or benefit of U.S. Persons (as defined in «Regulation S» under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws and (ii) may be offered, sold or otherwise delivered at any time only to transferees that are Non-United States Persons (as defined by the U.S. Commodities Futures Trading Commission). Investors are invited to carefully read the Product documentation, namely the Base Prospectus, which may be amended or supplemented from time to time, together with the relevant Final Terms prepared for a particular Product containing the full legally binding terms and conditions.

© Helveteq AG, Zentrum Staldenbach 3, 8808 Pfäffikon SZ, Switzerland. 2025. All rights reserved.

WARHOL MAO72 CHF TRACKER CERTIFICATE

Investing in Blue-Chip Art. Andy Warhol ranked as the 2nd top-selling artist at auction between 2015 and 2023 by lot sold with total sales reaching.

ADVERTISING

FACTSHEET AS OF AUGUST 2025

PRODUCT ADVANTAGES

SIMPLE

It is planned to list this product on ARTEX GM. At the time of the issue date, no application has been submitted. This product is initially issued as a non-listed Exchange Traded Product (nETP), structured as a collateralised tracker certificate. While similar to traditional ETPs, nETPs are not listed on a stock exchange. Like ETPs, they are backed by collateral to minimise issuer credit risk. Because they are not exchange-traded, nETPs can offer exposure to a broader range of underlying assets.

REGULATED

All nETPs are issued under the Base Prospectus of Helveteq. The Base Prospectus was approved by and registered with SIX Exchange Regulation Ltd, the reviewing body within the meaning of the Swiss Financial Services Act.

SECURE

An independent Security Agent safeguards the collateral for investors, using the underlying assets as security. These assets are held in segregated accounts with a third-party custodian. While the product is fully collateralized to reduce issuer credit risk, it does not protect against fluctuations in the market value of the underlying assets. The net asset value (NAV) is independently verified each month by a regulated administrator.

TRANSPARENT

nETPs issued by Helveteq are always ESG-transparent. This means the ESG focus is clearly designated in the product's Final Terms.

NAV PERFORMANCE INDICATORS

MONTHLY CHANGE (%)

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
25'												

PROSPECTUS: https://helveteq.com/wp-content/uploads/2024/05/HELVETEQ-Base_Prospectus_2024.pdf

ARTEX

GLOBAL MARKETS

REFERENCE - DATA

Issuer:	Helveteq AG
Valor:	144275696
ISIN:	CH1442756966
Currency:	CHF
Issue price:	CHF 92 – CHF 94
Issue size securities:	up to 137'500
Revenue:	long-term growth

TRADE DATA

Issue date:	30 Sep 2025
Subscription period:	27. Apr 2025 until 26. Sep 2025
Maturity:	open end
Investor Fee:	0.25% p.a.
Subscription Fee:	up to 100%

SERVICE PROVIDER

Custodian:	Credinvest
Paying Agent:	Credinvest
Administrator:	Apex
Security Agent:	Adexas

CONTACT

Helveteq AG
Zentrum Staldenbach 3
8808 Pfäffikon SZ
Schweiz
+41 (0)41 554 50 99
info@helveteq.com
www.helveteq.com

*DISCLAIMER

Nothing in this transmission constitutes, may be used for the purpose of, or may be construed as, an invitation, an offer or a solicitation of securities for sale or for subscription in any jurisdiction where it is unlawful to do so. The information is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this transmission or its accuracy or completeness. The information in this transmission is subject to change. Past performance is not an indication or guarantee of future results. The charts and graphs may reflect hypothetical historical performance. All information presented prior to the issue date is back-tested. Back-tested performance is not actual performance but is hypothetical. The Products do not constitute collective investment schemes within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA), as amended from time to time, and are, therefore, neither governed by the CISA nor subject to authorization and supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, holders of these Products do not have the benefit of the specific investor protection provided under the CISA. The Issuer is not and will not be regulated by any regulator as a result of issuing the Products. The issuer is neither licensed nor registered with the Swiss Financial Market Supervisory Authority (FINMA).

THE PRODUCTS ARE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR ANY PERSON OR ADDRESS IN THE UNITED STATES OR IN ANY OTHER JURISDICTION TO WHICH A DISTRIBUTION WOULD BE UNLAWFUL. The Products have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act) or with any securities regulatory authority of any State or other jurisdiction of the United States and (i) may not be offered, sold or delivered within the United States to, or for the account or benefit of U.S. Persons (as defined in «Regulation S» under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws and (ii) may be offered, sold or otherwise delivered at any time only to transferees that are Non-United States Persons (as defined by the U.S. Commodities Futures Trading Commission). Investors are invited to carefully read the Product documentation, namely the Base Prospectus, which may be amended or supplemented from time to time, together with the relevant Final Terms prepared for a particular Product containing the full legally binding terms and conditions.

© Helveteq AG, Zentrum Staldenbach 3, 8808 Pfäffikon SZ, Switzerland. 2025. All rights reserved.